share_log

HC Wainwright & Co. Reiterates Buy on Prelude Therapeutics, Maintains $17 Price Target

HC Wainwright & Co. Reiterates Buy on Prelude Therapeutics, Maintains $17 Price Target

HC Wainwright & Co.重申买入 Prelude Therapeutics,维持17美元的目标股价
Benzinga ·  2023/08/17 06:32

HC Wainwright & Co. analyst Robert Burns reiterates Prelude Therapeutics (NASDAQ:PRLD) with a Buy and maintains $17 price target.

HC Wainwright&Co.分析师罗伯特·伯恩斯重申Prelude Treateutics(纳斯达克:PRLD)的买入,并维持17美元的目标价。

声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    抢沙发